Merck KGaA - Biotech Market Share Report

Merck Market Share Report graphic featuring Merck, Erbitux and Rebif logosCompany: Merck KGaA
2007 Sales: $2.7 billion
Market share: 3.6%
CAGR: 17.9%

What they have: When Merck KGaA bought out Serono in 2006 it inherited Rebif, a top-selling multiple sclerosis drug. Merck is also one of three companies partnered on cancer drug Erbitux (along with ImClone and Bristo-Myers Squibb, which are not on this list). The drug is approved for head and neck and colorectal cancer.

What to look for: Merck KGaA has filed two additional indications for Erbitux and has a new formulation of Rebif in the works. The company is also cunducting late-stage testing for atacicept, an experimental rheumatoid arthritis treatment.

Merck KGaA - Biotech Market Share Report

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i